

## **Remarks**

Claims 1-47 are pending in the instant application. Applicants have amended claims 1-11, 13-27, 31-33 and 37-47 to more fully conform with U.S. practice. The amendments do not constitute new matter.

The enclosed substitute specification in compliance with 37 CFR 1.121(b)(3) and 1.125 is for publication purposes and does not contain any markings. It includes a new first paragraph cross referencing the related priority applications. It also includes a reference to color drawings. Applicants enclose herewith a "Petition for Color Drawings" with fee for consideration.


Applicants provide herewith copies of the published international application, the international search report and the search report from the Great Britain Patent Office. Also enclosed is Form PTO-1449 listing the cited references with copies of the non-US citations. Further, Applicants file herewith a Submission of Sequence Listing, a printed copy of the sequence listing and a diskette containing the computer readable form of the sequence listing.

A signed combined Declaration and Power of Attorney is also enclosed.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry.

Applicants believe that the claims, as amended, are in allowable form and earnestly solicited the allowance of claims 1-47.

Respectfully submitted,

  
Yonggang Ji  
Registration No.: 53,073  
Agent for Applicants

**Customer No.: 22840**

GE Healthcare Bio-Sciences Corp.  
Patent Department  
800 Centennial Avenue  
Piscataway, New Jersey 08855-1327

Tel: (732) 980-2875  
Fax: (732) 457-8463